Skip to content
Menu

Can-Fite BioPharma Ltd. CANF

Full chart Compare
Set alert

Price alert · CANF

All alert types
1.44 USD -0.03 (-2.34%)

As ofNov 20, 2026, 3:59 PM EST

1.43 Day range 1.53
1.42 52-week range 7.80
YTD
-64.13%
1 year
-76.85%

Fundamental scorecard

6 of 25 checks passed on CANF’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Value 2 of 5

  • Failed:P/E below its own 5-year median No profit over FY 2025, so no P/E.
  • Failed:P/E under 20 No profit over FY 2025, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 10.7 against a 5-year median of 13.4.
  • Passed:Price to book below its own 5-year median Price to book 0.9 against a 5-year median of 1.7.
  • Failed:Free cash flow yield above 4% Free cash flow of -8.95M is -205.8% of the market value.

Growth 1 of 5

  • Failed:Revenue grew over the last year Revenue of 405K is -39.9% on the year before.
  • Failed:Revenue grew more than 5% a year over five years -11.9% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS -11.94 against -21.72 in the year before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -240.00 in FY 2020, -11.94 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -9.83M over FY 2025.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -191.0%.
  • Failed:Net margin above its 5-year average Net margin of -2426.7% against a 5-year average of -1471.6%.
  • Failed:Free cash flow is at least 80% of net income No profit over FY 2025 to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 8.00M against short-term liabilities of 2.23M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 8.00M against long-term liabilities of 975K.
  • Passed:Net debt under 40% of equity More cash than debt: 7.04M of cash against 49.0K of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -8.95M is -18263.3% of debt.
  • No data:Operating profit covers interest at least 3 times Not enough data to decide.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What CANF owns and owes, as of Jun 30, 2026

Short term and long term

Balance sheet · 8.05M of assets

Debt, equity and cash by year

Now: 6.99M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

-34.09 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C+2 / 5 overall

  • DCF 2
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 4
  • P/E 1
  • P/B 3

Valuation

P/E -49.9×
P/S 1211×
P/B 88.4×
P/FCF -54.8×
EV/EBITDA -48.9×
EV/Sales 1198×
FCF Yield -1.8%

Profitability

Gross Margin 94.1%
Operating Margin -2456.8%
Net Margin -2426.7%
ROE -177.1%
ROIC -146.6%
ROA -104.1%

Growth (YoY)

Revenue -39.4%
Operating Income -23.4%
EPS (diluted) -1013.9%
Free Cash Flow -18.1%

Financial Health

Current Ratio 3.5×
Quick Ratio 3.5×
Debt / Equity 0.0×
Net Debt / EBITDA 0.5×
Interest Coverage -711×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31